The epilepsy therapeutic market in APAC to grow at a CAGR of 4.25% during the period 2017-2021.
Epilepsy Therapeutic Market in APAC 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market. To calculate the market size, the report considers the sales of branded, generic, and off label drugs.
The latest trend gaining momentum in the market is reformulation of marketed drugs. Drug delivery systems such as transdermal patches, extended-release (ER) formulations, and orally disintegrating tablets increase the efficacy of drugs either by increasing the patient compliance or by increasing the bioavailability of the drug. The reformulation of marketed drugs also provides an opportunity to grab patent term extensions, which can delay the entry of generic versions in the market.
According to the report, one of the major drivers for this market is high unmet medical need. The epilepsy therapeutics market in APAC is currently witnessing a high unmet medical need in terms of the lack of any disease-modifying treatment.
Other prominent vendors
- Dainippon Sumitomo Pharma
- Janssen Pharmaceutical (a division of Johnson & Johnson)
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Research Methodology
Part 04: Introduction
Part 05: Disease overview
Part 06: Market landscape
Part 07: Pipeline analysis
Part 08: Market segmentation based on product type
Part 09: Geographical segmentation
Part 10: Decision framework
Part 11: Drivers and challenges
Part 12: Market trends
Part 13: Vendor landscape
Part 14: Key vendor analysis
Part 15: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/hqqz7d/epilepsy